TLR8 agonists decrease production of cAMP in tumor cells and inhibit glycolysis in tumor-derived Tregs, but do not interfere with effector T cell metabolism, thus preventing senescence of tumor-killing TILs without limiting their function [106,125]. This evidence concerns the gene TLR8 and neoplasm.